-
Raltegravir Is a Potent Inhibitor of XMRV, a Virus Implicated in Prostate Cancer and Chronic Fatigue Syndrome
Ila R. Singh1*, John E. Gorzynski1, Daria Drobysheva1, Leda Bassit2, Raymond F. Schinazi2 1 Department of Pathology, University of Utah, Salt Lake City, Utah, United States of America, 2 Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Veterans Affairs Medical Center, Decatur, Georgia, United States of America.
-
Nexavir (Kutapressin) for ME/CFS
With thanks to a blog of cfssufferer. http://livingwithchronicfatiguesyndrome.wordpress.com/. Nexavir may improve ME/CFS symptoms because it: 1. Inhibits EBV, 2. Inhibit HHV-6, 3. Is anti-inflammatory, 4. Is antiviral, 5. Is an immunomodulator (Nexavir may help shift the immune system away from Th2 dominance.), 6. Enhances blood flow in the brain (as measured by a SPECT scan.). This increased rate of blood flow may be a consequence of the Bradykinin effect which involves dilation of the blood vessels.
-
Kenny de Meirleir Antivirals Treatment at Satellite Meeting 2008
"Antiviral treatment strategies in Chronic Fatigue Syndrome" International Symposium on Viruses in CFS & Post-viral Fatigue A satellite meeting of the 6th International Conference on HHV-6 & 7 in Baltimore, Maryland, USA Day 4 - June 23, 2008 - Clinician Forum Session
-
A six-month trial of Valacyclovir in the Epstein-Barr virus subset of Chronic Fatigue Syndrome: Improvement in left ventricular function
Lerner AM, Beqaj SH, Deeter RG, Dworkin HJ, Zervos M, Chang CH, Fitzgerald JT, Goldstein J, O'Neill W.
-
Successful Intravenous Immunoglobulin Therapy of Parvovirus B19
J. R. Kerr, V. S. Cunniffe, P. Kelleher, R. M. Bernstein, and I. N. Bruce
News
- 15.06.2009 Think Tank mentioned on Sky News
- 08.06.2009 Conference on ME/CFS in Stavanger is open for patients and relatives
- 27.01.2012 Persbericht: Petitie ME-patiënten: Erken ME als invaliderende biomedische ziekte
- 24.01.2012 Response to ‘A controversial consensus’; By the International Consensus Panel, Journal of Internal Medicine
- 24.01.2012 A controversial consensus – comment on article by Broderick et al, Journal of Internal Medicine